Thus, the results of the study conducted by Kusano et al (109) indicate that combination therapy may be a more effective strategy for the treatment of HCC cases with variable sensitivity to the antitumor effects of singular sorafenib or PEG-IFN-α2b therapy. Here, IFNA2 is linked to hepatocellular carcinoma.